Therapeutic microvesicles of probiotic bacteria
Inventors
Roos, Stefan • Kunze, Wolfgang • Bienenstock, John
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11857582-B2
Publication Date
2024-01-02
Expiration Date
Abstract
A method to provide therapeutic microvesicles from probiotic bacteria comprises exposing the bacteria to an inducing treatment during culturing to induce production of therapeutic microvesicles by the bacteria. The therapeutic microvesicles may be used in treatment of, for instance, colic, an infant or childhood gastrointestinal disorder or disease, a gastrointestinal pain disorder, a bone loss disease and/or a periodontal disease.
Core Innovation
The invention relates to therapeutic microvesicles derived from probiotic bacteria. It describes inducing biotic treatments, including co-culture with another strain or culturing with conditioned medium from another strain, to generate therapeutic microvesicles.
It further describes inducing abiotic treatments to promote therapeutic microvesicle generation from probiotic bacteria, including oxidative or oxygen stress, temperature stress, pH stress, UV stress, and stress-inducing agents. The induced or probiotic-derived microvesicles are stated to recapitulate probiotic effects on gut motility and pain signaling.
The induced or probiotic-derived microvesicles are also stated to show immune modulation and to protect epithelial barrier integrity against ETEC. They are described as fast-acting compared with parent bacteria.
Claims Coverage
The provided material includes 1 independent claim. The claim coverage is directed to an isolated bacterial strain with drying or lyophilization, and the summarized dependent matter adds probiotic composition context and a functional capability relating to inducing therapeutic microvesicle production by another bacteria.
Isolated Bifidobacterium longum as dried or lyophilized strain
An isolated bacterial strain wherein the bacterial strain is Bifidobacterium longum DSM 32947 or Bifidobacterium longum DSM 32948, wherein the bacterial strain is dried or lyophilized.
The core claim coverage is a dried or lyophilized isolated Bifidobacterium longum strain, specifically DSM 32947 or DSM 32948, with additional summarized material referring to strain selection, composition context, and induction of therapeutic microvesicle production by another bacteria.
Stated Advantages
Induced or probiotic-derived MVs recapitulate probiotic effects on gut motility and pain signaling.
Induced or probiotic-derived MVs act faster than parent bacteria.
Induced or probiotic-derived MVs show immune modulation, including dampening IFN-γ and IL-17A and increasing IL-6.
Induced or probiotic-derived MVs protect epithelial barrier integrity against ETEC.
Documented Applications
Treating infant colic.
Treating gastrointestinal disorders, including gastrointestinal pain.
Treating bone loss disease, including osteopenia and osteoporosis.
Treating periodontal disease.
Interested in licensing this patent?